|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rekhtman N, Leighl NB and Somerfield MR:
Molecular testing for selection of patients with lung cancer for
epidermal growth factor receptor and anaplastic lymphoma kinase
tyrosine kinase inhibitors: American society of clinical oncology
endorsement of the college of American pathologists/international
association for the study of lung cancer/association for molecular
pathology guideline. J Oncol Pract. 11:135–136. 2015. View Article : Google Scholar
|
|
3
|
Solomon B, Varella-Garcia M and Camidge
DR: ALK gene rearrangements: A new therapeutic target in a
molecularly defined subset of non-small cell lung cancer. J Thorac
Oncol. 4:1450–1454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Ostoros G, Cobo M, Ciuleanu
T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T
and McCormack R: Gefitinib treatment in EGFR mutated caucasian
NSCLC: Circulating-free tumor DNA as a surrogate for determination
of EGFR status. J Thorac Oncol. 9:1345–1353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmidt B, Engel E, Carstensen T,
Weickmann S, John M, Witt C and Fleischhacker M: Quantification of
free RNA in serum and bronchial lavage: A new diagnostic tool in
lung cancer detection? Lung Cancer. 48:145–147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross K, Pailler E, Faugeroux V, Taylor M,
Oulhen M, Auger N, Planchard D, Soria JC, Lindsay CR, Besse B, et
al: The potential diagnostic power of circulating tumor cell
analysis for non-small-cell lung cancer. Expert Rev Mol Diagn.
13:1605–1629. 2015. View Article : Google Scholar
|
|
7
|
Pailler E, Adam J, Barthélémy A, Oulhen M,
Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, et al:
Detection of circulating tumor cells harboring a unique ALK
rearrangement in ALK-positive non-small-cell lung cancer. J
ClinOncol. 31:2273–2281. 2013. View Article : Google Scholar
|
|
8
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faugeroux V, Pailler E, Auger N, Taylor M
and Farace F: Clinical utility of circulating tumor cells in
ALK-positive non-small-cell lung cancer. Front Oncol. 4:2812014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo K, Nishio M, Sakai K, Tanimoto A,
Sakatani T and Saito R: Detection of EML4-ALK in serum RNA from
lung cancer patients using MassARRAY platform. J Clin Oncol.
30:suppl; abstr 10569. 2012.
|
|
11
|
Nilsson RJ, Karachaliou N, Berenguer J,
Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL,
Drees E, Grabowska M, et al: Rearranged EML4-ALK fusion transcripts
sequester in circulating blood platelets and enable blood-based
crizotinib response monitoring in non-small-cell lung cancer.
Oncotarget. 7:1066–1075. 2016.
|
|
12
|
Gabriel S, Ziaugra L and Tabbaa D: SNP
genotyping using the Sequenom MassARRAY iPLEX platform. Curr
Protocs Human Genet. Chapter 2: Unit 2.12. 2009. View Article : Google Scholar
|
|
13
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong M, Kim RN, Song JY, Choi SJ, Oh E,
Lira ME, Mao M, Takeuchi K, Han J, Kim J and Choi YL: HIP1-ALK, a
novel fusion protein identified in lung adenocarcinoma. J Thorac
Oncol. 9:419–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi YL, Lira ME, Hong M, Kim RN, Choi SJ,
Song JY, Pandy K, Mann DL, Stahl JA, Peckham HE, et al: A novel
fusion of TPR and ALK in lung adenocarcinoma. J Thorac Oncol.
9:563–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cameron L and Solomon B: Treatment of
ALK-rearranged non-small cell lung cancer: Recent progress and
future directions. Drugs. 75:1059–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cabillic F, Gros A, Dugay F, Begueret H,
Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D,
Corre R, et al: Parallel FISH and immunohistochemical studies of
ALK status in 3244 non-small-cell lung cancers reveal major
discordances. J Thorac Oncol. 9:295–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H,
Wang R, Ye T, Luo X, Zhang Y, et al: ALK, ROS1 and RET fusions in
1139 lung adenocarcinomas: A comprehensive study of common and
fusion pattern-specific clinicopathologic, histologic and cytologic
features. Lung Cancer. 84:121–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeuchi K, Choi YL, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, et
al: Multiplex reverse transcription-PCR screening for EML4-ALK
fusion transcripts. Clin Cancer Res. 14:6618–6624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soda M, Isobe K, Inoue A, Maemondo M,
Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, et
al: A prospective PCR-based screening for the EML4-ALK oncogene in
non-small cell lung cancer. Clin Cancer Res. 18:5682–5689. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Q, Deng Q, Jiang L, Fang R, Qiu Y,
Wang P, Zhou JX and Yang H: Assessment of ALK gene fusions in lung
cancer using the differential expression and exon integrity
methods. Oncol Lett. 11:1651–1656. 2016.PubMed/NCBI
|
|
24
|
Zito Marino F, Liguori G, Aquino G, La
Mantia E, Bosari S, Ferrero S, Rosso L, Gaudioso G, De Rosa N,
Scrima M, et al: Intratumor heterogeneity of ALK-rearrangements and
homogeneity of EGFR-mutations in mixed lung adenocarcinoma. PLoS
One. 10:e01415212015. View Article : Google Scholar
|
